drugset / Trial / NCT07021261
Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the IDFS rate, overall survival (OS) rate, and safety profile of UTD2 combined with capecitabine versus capecitabine monotherapy as adjuvant therapy for triple-negative early breast cancer patients who did not achieve pathological complete response (pCR) after neoadjuvant therapy.
Timeline
- Start
- 2025-06-16
- Primary completion
- 2030-06-16
- Completion
- 2032-06-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Epothilone D | Small molecule | 50 mg/m2 | Oral |